A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (BRAVE I)

First filed August 2018, Updated March 2019

CATEGORIES: General SLE

The reason for this randomized, double-blind, placebo-controlled, parallel-group, phase 3 study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

To Learn More Contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
Mon – Fri 9 AM – 5 PM Eastern time (UTC/GMT – 5 hours, EST)Eli Lilly and Company
ClinicalTrials.gov identifier: NCT03616912

Learn More

Role of PPAR-y Anonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

First filed January 2015, updated December 2018

CATEGORIES: General SLE

This Phase 1/2 randomized study sponsored by the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is looking at how well pioglitazone improves blood vessel function and decreases blood vessel inflammation for patients with lupus. The study is being conducted at the NIH Clinical Center in Bethesda, Maryland.

To Learn More Contact
Call 800-411-1222 ext or prpl@mail.cc.nih.gov
ClinicalTrials.gov identifier: NCT02338999

Learn More

A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

first filed January 2016, updated June 2018

CATEGORIES: General SLE

This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus. The trial is sponsored by Resolve Therapeutics.

To Learn More Contact
James Posada, Ph.D. at 208 727 7010 or jp@resolvebio.com
ClinicalTrials.gov identifier: NCT02660944

Learn More

A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE)

First filed November 2016, updated March 2018

CATEGORIES: General SLE

The goal of this multicenter, randomized, double blind, placebo controlled study is to assess the efficacy and safety of H.P. Acthar® Gel in people with persistently active Systemic Lupus Erythematosus despite moderate dose corticosteroids.

To Learn More Contact
George Omburo, PhD at 908-238-6786 or george.omburo@mallinckrodt.com
ClinicalTrials.gov identifier: NCT02953821

Learn More

Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) (LILAC)

First filed June 2016, updated November 2018

CATEGORIES: General SLE

The primary objective of the study is to evaluate the efficacy of BIIB059 in reducing skin disease activity in participants with systemic lupus erythematosus (SLE) (Part A), and in participants with active cutaneous lupus erythematosus (CLE) with or without systemic manifestations (Part B), and to investigate the dose response relationship in participants with active SLE and skin manifestations (Part A only). Secondary objective is to evaluate additional efficacy parameters of BIIB059 in reducing SLE disease activity. Study sponsor: Biogen

To Learn More Contact
Biogen at clinicaltrials@biogen.com
ClinicalTrials.gov identifier: NCT02847598